We have located links that may give you full text access.
Robotic stereotactic boost in early breast cancer, a phase II trial.
International Journal of Radiation Oncology, Biology, Physics 2018 October 27
PURPOSE: to evaluate the feasibility and toxicity of a single 8Gy-fraction stereotactic boost after whole breast irradiation (WBI) in early breast cancer. The primary aim of this phase II study was to evaluate cutaneous breast toxicity utilizing CTC-AEv4 three months after the boost. Secondary objectives were local control, survival and patient-reported quality of life using the EORTC QLQ-C30 and breast specific EORTC QLQ-BR 23 questionnaires.
METHODS AND MATERIALS: Patients with invasive ductal or lobular, pT1-2 breast cancer treated with lumpectomy with clear margins and pN0 were included. Patients requiring chemotherapy were excluded.
RESULTS: 28 eligible patients received the planned boost and 26 had hormonal therapy. The procedure was technically successful without procedural complications. A median of three fiducials were tracked and 115 beams were used. There were 22 acute grade-1 breast skin toxicities including fibrosis, pain, erythema or pigmentation. There were two acute grade 2 erythemas. Median skin boost dose was inversely correlated with acute skin toxicity (p=0.028). QLQ-C30 scores revealed acute dyspnea and arm symptoms without correlation to the boost dose. Breast symptom QLQ-BR23 scores did not deteriorate while upset by hair loss and systemic side-effects of hormonal therapy were observed. After a median follow-up of 38 months, one patient had in-boost field relapse and there were 5 late grade 1 and 1 grade 2 skin toxicities.
CONCLUSION: Single-fraction stereotactic boost after conventional WBI in early breast cancer is feasible in minor toxicities. Quality of life and specific breast items showed excellent patient acceptance.
METHODS AND MATERIALS: Patients with invasive ductal or lobular, pT1-2 breast cancer treated with lumpectomy with clear margins and pN0 were included. Patients requiring chemotherapy were excluded.
RESULTS: 28 eligible patients received the planned boost and 26 had hormonal therapy. The procedure was technically successful without procedural complications. A median of three fiducials were tracked and 115 beams were used. There were 22 acute grade-1 breast skin toxicities including fibrosis, pain, erythema or pigmentation. There were two acute grade 2 erythemas. Median skin boost dose was inversely correlated with acute skin toxicity (p=0.028). QLQ-C30 scores revealed acute dyspnea and arm symptoms without correlation to the boost dose. Breast symptom QLQ-BR23 scores did not deteriorate while upset by hair loss and systemic side-effects of hormonal therapy were observed. After a median follow-up of 38 months, one patient had in-boost field relapse and there were 5 late grade 1 and 1 grade 2 skin toxicities.
CONCLUSION: Single-fraction stereotactic boost after conventional WBI in early breast cancer is feasible in minor toxicities. Quality of life and specific breast items showed excellent patient acceptance.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app